NTLA

Intellia Therapeutics is a leading genome editing company developing CRISPR/Cas9-based therapies to treat genetic diseases. The company is advancing both in vivo (directly in the body) and ex vivo (cell therapy) programs targeting conditions including transthyretin amyloidosis, hereditary angioedema, and various cancers using its proprietary CRISPR platform.